Testing brain signals to predict response to ECT
Part of Brain & nervous system, Mental health clinical trials.
This study looks at “neural biomarkers,” or brain-measurement signals, to see who is most likely to benefit from electroconvulsive therapy (ECT). It focuses on people with certain active psychosis symptoms and specific mental health diagnoses who have tried antipsychotic medication without enough improvement.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You currently have moderate or worse psychosis symptoms (rated at least 4) such as unusual thoughts, suspiciousness, odd behavior, or disorganized thinking
- You have tried at least one antipsychotic medicine for 6 weeks and it did not work well enough
- You can understand the study and are willing to sign consent
- If you are able to get pregnant: you have a negative pregnancy test and agree to reliable birth control
- You have a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder (DSM-IV)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors find the best settings for electroconvulsive therapy (ECT), a treatment for severe depression and other mental health conditions. Researchers will use special monitoring equipment to measure brain activity during your ECT sessions to improve how the treatment works.
This study looks for ways to predict how well electroconvulsive therapy (ECT) will work for severe depression. It may help doctors choose the best treatment approach and timing for future patients.
This study looks at how ECT affects brain activity and inflammation in older adults with depression. It may help researchers understand why ECT works and improve treatment.
This study measures changes in your blood and/or body chemistry while you receive electroconvulsive therapy (ECT) for a severe mood episode. The goal is to understand biological signals related to ECT and treatment-resistant depression, which may help improve future care.
This study looks at brain wave patterns and markers of inflammation in people with depression that hasn't improved with other treatments and who are receiving electroconvulsive therapy (ECT, also known as shock therapy). The goal is to understand how these markers might relate to how well ECT works.
This trial studies signs in the brain (biomarkers) during an accelerated form of nerve stimulation to treat depression that hasn’t improved with usual antidepressants. It may help researchers learn who benefits and how to better personalize treatment.
Hear when a new Electroconvulsive Therapy Treated Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.